Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. | Front Immunol | 2023 | 37409132 | PubTator, text mining | PubMed |
| Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer. | Front Oncol | 2023 | 37404760 | PubTator, text mining | PubMed |
| Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers. | Front Immunol | 2023 | 37398650 | PubTator, text mining | PubMed |
| Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. | Genes Dis | 2023 | 37397537 | PubTator, text mining | PubMed |
| The recent progress of peptide regulators for the Wnt/β-catenin signaling pathway. | Front Med (Lausanne) | 2023 | 37396899 | PubTator, text mining | PubMed |
| CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases. | Front Immunol | 2023 | 37377956 | PubTator, text mining | PubMed |
| Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses. | Pharmaceutics | 2023 | 37376133 | PubTator, text mining | PubMed |
| A Comparison of Lymphoid and Myeloid Cells Derived from Human Hematopoietic Stem Cells Xenografted into NOD-Derived Mouse Strains. | Microorganisms | 2023 | 37375051 | PubTator, text mining | PubMed |
| Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. | Biomedicines | 2023 | 37371615 | PubTator, text mining | PubMed |
| Exosomes: A Promising Strategy for Repair, Regeneration and Treatment of Skin Disorders. | Cells | 2023 | 37371095 | PubTator, text mining | PubMed |
| Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer. | Cancers (Basel) | 2023 | 37370686 | PubTator, text mining | PubMed |
| Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery. | Adv Drug Deliv Rev | 2023 | 37369262 | PubTator, text mining | PubMed |
| New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. | Cancer Metastasis Rev | 2023 | 37368179 | PubTator, text mining | PubMed |
| Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens. | Cancer Immunol Immunother | 2023 | 37368077 | PubTator, text mining | PubMed |
| Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes. | Front Immunol | 2023 | 37359554 | PubTator, text mining | PubMed |
| Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia. | Cancers (Basel) | 2023 | 37345068 | PubTator, text mining | PubMed |
| Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. | Cancers (Basel) | 2023 | 37345057 | PubTator, text mining | PubMed |
| Tissue-specific cancer stem/progenitor cells: Therapeutic implications. | World J Stem Cells | 2023 | 37342220 | PubTator, text mining | PubMed |
| Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. | Mol Oncol | 2023 | 37341056 | PubTator, text mining | PubMed |
| Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA). | Sci Rep | 2023 | 37336938 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=11